Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis.

ABSTRACT:

Background

The refractory/relapsed multiple myeloma (RRMM) remains a big clinical challenge, due to its biological and clinical complexity. Leading hematologists have performed many randomized controlled trials (RCTs) worldwide, and their findings were summarized in a recently published network meta-analysis (NMA) but with certain limitations.

Materials and methods

We performed an updated NMA of RCTs related to RRMM treatment, focusing on efficacy measures including the nonresponse rate (NRR), time to progression (TTP), progression-free survival (PFS), and overall survival (OS). The PubMed database was searched. We extended the literature search strategy of a previous NMA to June 30, 2017 and included additional primary RCTs. The surface under the cumulative ranking curve (S

SUBMITTER: Luo XW 

PROVIDER: S-EPMC6109665 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature